A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE).
2022-06-29
عنوان الدراسة
A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE).
داعم الدراسة
Novartis
دواء الدراسة
LJN452
رقم بروتوكول الدراسة
CLJN452D12201C
حالة الدراسة
Ongoing
موقع الدراسة
King Fahad Medical City (Riyadh)
مرحلة الدراسة
2b
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。